Get the weekly note

Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

IBB vs ITOT: how they differ

IBB and ITOT hold 2% of their weight in the same names, and IBB returned more over the year.

iShares Biotechnology ETF and iShares Core S&P Total U.S. Stock Market ETF.

What they hold in common

By the books each fund has filed, IBB and ITOT hold 2% of their money in the same securities at the same weight.

Positions IBB and ITOT both hold, largest shared weight first
HoldingIBBITOT
AMGEN INC7.85%0.28%
GILEAD SCIENCES7.44%0.24%
VERTEX PHARMACEUTICALS7.94%0.18%
REGENERON PHARMACEUTICALS5.92%0.11%
BLK CSH FND TREASURY SL AGENCY0.12%0.07%
MODERNA3.67%0.07%
NATERA3.30%0.06%
REVOLUTION MEDICINES2.87%0.06%
USD CASH0.05%0.09%
ALNYLAM PHARMACEUTICALS2.44%0.04%
BIOGEN2.33%0.04%
ILLUMINA INC2.25%0.04%
Largest positions each one holds and the other does not
Only in IBBOnly in ITOT
ARGENX SE ADR 3.78%NVIDIA 7.32%
BEONE MEDICINES AG 2.01%APPLE 6.63%
GENMAB SPONSORED ADR 1.25%MICROSOFT 5.06%
ASCENDIS PHARMA 1.20%AMAZON.COM INC 3.41%
BIONTECH SE ADR 0.65%ALPHABET CLASS A 2.70%
ABIVAX AMERICAN DEPOSITARY SHARES 0.55%BROADCOM INC 2.37%
XENON PHARMACEUTICALS 0.40%ALPHABET CLASS C 2.16%
ACADIA PHARMACEUTICALS 0.35%META PLATFORMS CLASS A 1.96%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.

IBB and ITOT on the fields both publish, as of Sep 13, 2026. Source: ETFIQ.
IBB
iShares Biotechnology ETF
ITOT
iShares Core S&P Total U.S. Stock Market ETF
Where it sitsCore index fundCore index fund
IssueriSharesiShares
What it isBiotechnologyCore S&P Total U.S. Stock Market
Total return, 1 year+41.5%+17.2%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500+24.0 pts−0.3 pts
Expense ratio0.44%0.03%
Already in the S&P 50035.6%88.3%
Holdings2331167

IBB in plain words

IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Sep 10, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 233 positions, with the top ten at 47.5%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.

ITOT in plain words

ITOT is an index equity fund tracking the Core S&P Total U.S. Stock Market. Over the year to Sep 11, 2026 it returned +17.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for Sep 10, 2026, 88% of the fund by weight is stocks the S&P 500 also holds, across 1167 positions, with the top ten at 34.6%.

Questions people ask

Which returned more over the last year, IBB or ITOT?
In the year to Sep 13, 2026, with distributions reinvested, IBB returned +41.5% and ITOT returned +17.2%, so IBB returned more. One year is one year; the longer windows are in the table.
Which is cheaper, IBB or ITOT?
IBB charges 0.44% a year and ITOT charges 0.03%, so ITOT is cheaper. Fees come from each fund's prospectus.
How much do IBB and ITOT overlap with the S&P 500?
By their latest filed holdings, 36% of IBB and 88% of ITOT by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

IBB against ITOT, ETFIQ, data as of Sep 13, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, IBB against ITOT, data as of Sep 13, 2026. https://etfiq.com/compare/any/ibb-vs-itot Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources